Long-term survival after gastrectomy for cancer in randomized, controlled oncological trials: Comparison between west and east

Annals of Surgical Oncology

Volumn 20, Issue 7, 2013, Pages 2328-2338

  Markar, Sheraz R ^a   Karthikesalingam, Alan ^b   Jackson, Daniel ^c   Hanna, George B ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; METHOTREXATE; MITOMYCIN; UFT;

ADJUVANT THERAPY; AGE DISTRIBUTION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONFOUNDING VARIABLE; DEMOGRAPHY; DISEASE ASSOCIATION; GASTRECTOMY; HUMAN; LONG TERM SURVIVAL; LYMPH NODE; LYMPH NODE METASTASIS; MEDICAL RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX RATIO; STOMACH CANCER; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CONFIDENCE INTERVALS; EUROPE; GASTRECTOMY; HUMANS; JAPAN; NEOADJUVANT THERAPY; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPUBLIC OF KOREA; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 84878866142     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2862-9     Document Type: Review

References (55)

1. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265:1287-9.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-50. (Pubitemid 46655601)
3. Noguchi Y, Imada T, Matsumoto A, et al. Radical surgery for gastric cancer. A review of the Japanese experience. Cancer. 1989;64:2053-62. (Pubitemid 19280403)
4. Griffin SM. Gastric cancer in the East: same disease, different patient. Br J Surg. 2005;92:1055-6. (Pubitemid 41284867)
5. Park DJ, Lee HJ, Kim HH, et al. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005;92:1099-102. (Pubitemid 41284874)
6. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453-62.
7. Bollschweiler E, Boettcher K, Hoelscher AH, et al. Is the prognosis for Japanese and German patients with gastric cancer really different? Cancer. 1993;71:2918-25. (Pubitemid 23145517)
8. Noguchi Y, Yoshikawa T, Tsuburaya A, et al. Is gastric carcinoma different between Japan and the United States? Cancer. 2000;89:2237-46.
9. Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010;251:640-6.
10. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522-30. (Pubitemid 29116815)
11. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908-14. (Pubitemid 29141051)
12. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439-49.
13. Bunt AM, Hermans J, van de Velde CJ, et al. Lymph node retrieval in a randomized trial on western-type versus Japanese-type surgery in gastric cancer. J Clin Oncol. 1996;14:2289-94. (Pubitemid 26264880)
14. Degiuli M, Sasako M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol. 2004;30:303-8. (Pubitemid 38425649)
15. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7:309-15.
16. Siewert JR, Kestlmeier R, Busch R, et al. Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg. 1996;83:1144-7. (Pubitemid 26291234)
17. Sue-Ling HM, Johnston D, Martin IG, et al. Gastric cancer: a curable disease in Britain. BMJ. 1993;307:591-6. (Pubitemid 23255064)
18. Anderson O, Ni Z, Moller H, et al. Hospital volume and survival in oesophagectomy and gastrectomy for cancer. Eur J Cancer. 2011;37:747-53.
19. Van Cutsem E, Dicato M, Geva R, et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona 2010. Ann Oncol. 2011;22(Suppl 5):v1-9.
20. McCulloch P, Niita ME, Kazi H, et al. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg. 2005;92:5-13. (Pubitemid 40144187)
21. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
22. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-30.
23. Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery along for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007;94:1468-76. (Pubitemid 350275624)
24. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet. 1999;354:273-7. (Pubitemid 29348734)
25. Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside following by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology group 9206-1. J Clin Oncol. 2003;12:2282-7. (Pubitemid 46621864)
26. Miyashiro I, Furukawa H, Sasako M, et al. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer. 2011;14:212-8.
27. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387-93.
28. Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of prospective randomized trial. World J Surg. 2011;25:985-90.
29. Nio Y, Koike M, Omori H, et al. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer - a single institute study. Anticancer Res. 2004;24:1879-87. (Pubitemid 38954602)
30. Bajetta E, Buzzoni R, Mariani L, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 2002;13:299-307. (Pubitemid 34704984)
31. Bouche O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005;16:1488-97. (Pubitemid 41226403)
32. Chipponi J, Huguier M, Pezet D, et al. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg. 2004;187:440-5. (Pubitemid 38299517)
33. De Vita F, Giuliani F, Orditura M, et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol. 2007;18:1354-8. (Pubitemid 47305009)
34. Di Costanzo F, Gasperoni S, Manzione L, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008;100:388-98. (Pubitemid 351480516)
35. Kulig J, Kolodziejczyk P, Sierzega M, et al. Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery along in the treatment of gastric cancer: a phase III randomized, multicenter clinical trial. Oncology. 2010;78:54-61.
36. Lise M, Marchet A, Sahmoud T, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in respectable gastric cancer. J Clin Oncol. 1995;13:2757-63.
37. Macdonald S, Fleming TR, Peterson RF, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alones for patients with locally advance gastric adenocarcinoma: A Southwest Oncology Group Study. Ann Surg Oncol. 1995;2:488-94.
38. Neri B, Cini G, Andreoli F, et al. Randomized trial of adjuvant chemotherapy versus control after curative resection of gastric cancer: 5-year followup. Br J Cancer. 2001;84:878-80. (Pubitemid 32385827)
39. Nitti D, Wils J, Guimaraes Dos Santos J, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and ICCG. Ann Oncol. 2005;17:262-9. (Pubitemid 43160116)
40. Popiela T, Kulig J, Czupryna A, et al. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer. 2004;7:240-5.
41. Tsavaris NB, Tendas K, Kosmidis P, et al. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy. 1996;42:220-6. (Pubitemid 26095178)
42. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-21.
43. Hartgrink HH, van de Velde CJH, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004;30:643-9. (Pubitemid 39060735)
44. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer Randomized trial 40954. J Clin Oncol. 2010;28:5210-8.
45. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18:2693-708. (Pubitemid 29481404)
46. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559-73. (Pubitemid 34746063)
47. White IR. Multivariate random-effects meta regression: updates to mvmeta. Stata J. 2011;11:255-70.
48. Higgins JP, Thompson SG. Quantifying heterogeneity in meta-analysis. Stata Med. 2002; 21: 1539-58. (Pubitemid 34746062)
49. Oh SJ, Hyung WJ, Li C, et al. Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma. J Gastroenterol Hepatol. 2009;24:475-9.
50. Kulig J, Sierzega M, Kolodziejczyk P, et al. Implications of overweight in gastric cancer: a multicenter study in a Western patient population. Eur J Surg Oncol. 2010;36:969-76.
51. Peters CJ, Rees JR, Hardwick RH, et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology. 2010;139:1995-2004.
52. McCulloch PG, Ochiai A, O'Dowd GM, et al. Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan. Cancer. 1995;75:920-5.
53. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315-21.
54. Seevaratnam R, Bocicariu A, Cardoso R, et al. A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer. 15;60-9.
55. Lewis WG, Edwards P, Barry JD, et al. D2 or not D2? The gastrectomy question. Gastric Cancer. 5:29-34.